Callidus Software Inc., the leading provider Sales Performance Management (SPM), today announced today the formation of its CallidusRX division, packaged solution that addresses pharmaceutical commercial models in managing direct and intermediary sales channels.
The division will be based in New York and will be led by Andrew Hahn, formerly managing partner of the Hahn Group. The new business unit expands Callidus Software’s market reach in the pharmaceutical and life science industry.
“Andrew Hahn is one of the foremost experts in pharmaceutical sales performance solutions in the world,” Leslie Stretch, president and CEO, Callidus Software stated in the press release. “We are delighted Mr. Hahn has joined us to lead this key Callidus business unit. The pharmaceutical market has unique needs in SPM. Our quota and territory planning, ranking, and commissions solutions are mission critical to sales growth in pharmaceutical businesses. The combination of our award-winning SaaS solutions and our new packaged services and BPO offering ensures that we are uniquely positioned for growth in this market.”
Hahn, who now serves as vice president of CallidusRX, Callidus Software, detailed the advantages and benefits the new division is expected to bring to Callidus Software.
- FOLLOW IBTIMES
“Callidus is the clear market leader in pharmaceutical sales performance solutions,” Hahn stated. “Callidus continues to out-invest and out-innovate all comers in their quest to deliver unmatched value to companies in the sector. This new division will allow us to be even more effective in delivering high quality solutions to this market. I am delighted to be appointed to lead the CallidusRX division and look forward to building on the broad portfolio of technology and service solutions that we bring to the marketplace.”
For more information visit www.callidussoftware.com
Small Cap News in collaboration with Quality Stocks